CENEXIS BIO | CNS Defense
...
...
CENEXIS BIO | CNS Defense
CONFIDENTIAL BRIEFING // [LLNL-02 / CX-101]

Beyond Survival.
Protecting the Cognitive Edge.

Cenexis Bio is developing the next generation of nerve agent antidotes. We are the execution bridge designed to preserve both life and brain function for U.S. and Allied stockpiles.

VIEW THE MISSION ↓
Strategic Analysis

The Status Quo is Grossly Inadequate

Nerve agents—including Sarin, VX, and Novichok—remain a credible and evolving threat in asymmetric conflicts. Current medical countermeasures (legacy oximes) save lives; however, they were designed for survival, not neuroprotection.

  • The Barrier: Existing legacy antidotes possess limited CNS penetration.
  • The Consequence: Survivors often suffer rapid, irreversible neurologic damage due to central seizure activity.
  • The Gap: There are currently no FDA-approved CNS-protective antidotes in the Strategic National Stockpile.
"Current countermeasures keep the victim alive but leave them unprotected from long-term neurologic injury."

BLOOD-BRAIN BARRIER: BLOCKED

Legacy oxime solutions fail to reach the brain effectively, leaving central nervous system targets vulnerable to irreversible damage.

TARGET: PENETRATED

LLNL-02 / CX-101

The first nerve-agent antidote engineered to cross the blood-brain barrier and preserve high-level cognitive function.

The Program

Next-Gen CNS-Penetrating Nerve Agent Antidote: LLNL-02 / CX-101

Developed at Lawrence Livermore National Laboratory (LLNL), LLNL-02 / CX-101 is engineered to replace the 60-year-old agents currently in the Strategic National Stockpile.

First-in-Class CNS Penetration

Designed by LLNL research scientists as a novel therapeutic capable of crossing the blood-brain barrier to stop seizures.

5x Longer Exposure

Pharmacokinetic data demonstrates approx. 5x longer durable systemic exposure than legacy antidotes.

Drop-In Readiness

Engineered as a superior replacement for legacy oximes, fully compatible with existing autoinjectors.

$7M
Gov Investment
LLNL
Research Origin
FDA
Animal Rule
USG
Validated Buyer
DE-RISKED EXECUTION: Cenexis Bio operates a mandated execution program aligned with U.S. national security requirements.
Execution Bridge

Regulatory & Industrial Roadmap

FDA Animal Rule Pathway (Accelerated Approval)

Navigating the specialized regulatory track for medical countermeasures where human efficacy trials are not feasible.

GMP Industrialization

Transitioning LLNL-02 into high-volume, domestic manufacturing for Strategic National Stockpile (SNS) / Medical Countermeasures.

Supply Chain Security

Ensuring domestic production resilience for critical nerve agent antidotes to mitigate foreign reliance.

Federal Procurement Data // CAGE & UEI

NAICS Codes: 541714, 325412

CAGE Code: 18W71

PSC / FSC: AN11 / 6505

Entity Status: U.S. Small Business

Project Governance

The Architects

Chief Executive Officer

Ray Stevens, MBA

Decades of experience in program execution and high-stakes biopharmaceutical leadership.

Chief Medical Officer

Stewart McCallum, MD FACS

20+ years of global development and regulatory expertise in the pharmaceutical industry.

Head, CMC & Quality

Dale Bennyhoff

25+ years in CMC, industrial scale-up, and GMP readiness for advanced therapeutics.

CBO / CFO

Bryan Katz, MBA

26-year pharma leader and U.S. Marine, focusing on the intersection of commerce and national defense.